278 related articles for article (PubMed ID: 24598210)
1. Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats.
Hye Khan MA; Neckář J; Haines J; Imig JD
Am J Hypertens; 2014 Aug; 27(8):1087-95. PubMed ID: 24598210
[TBL] [Abstract][Full Text] [Related]
2. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat.
Hye Khan MA; Neckář J; Cummens B; Wahl GM; Imig JD
Cardiovasc Drugs Ther; 2014 Aug; 28(4):313-22. PubMed ID: 24842561
[TBL] [Abstract][Full Text] [Related]
3. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat.
Hye Khan MA; Hwang SH; Sharma A; Corbett JA; Hammock BD; Imig JD
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():40-7. PubMed ID: 27432695
[TBL] [Abstract][Full Text] [Related]
4. Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.
Castoldi G; di Gioia CR; Bombardi C; Maestroni S; Carletti R; Steckelings UM; Dahlöf B; Unger T; Zerbini G; Stella A
Am J Physiol Renal Physiol; 2014 Nov; 307(10):F1123-31. PubMed ID: 25186297
[TBL] [Abstract][Full Text] [Related]
5. Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
Luo H; Wang X; Wang J; Chen C; Wang N; Xu Z; Chen S; Zeng C
Cardiovasc Diabetol; 2015 Jun; 14():76. PubMed ID: 26055622
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive and anti-inflammatory actions of combined azilsartan and chlorthalidone in Dahl salt-sensitive rats on a high-fat, high-salt diet.
Jin C; O'Boyle S; Kleven DT; Pollock JS; Pollock DM; White JJ
Clin Exp Pharmacol Physiol; 2014 Aug; 41(8):579-88. PubMed ID: 24798707
[TBL] [Abstract][Full Text] [Related]
7. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
8. Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade.
Sukumaran V; Tsuchimochi H; Tatsumi E; Shirai M; Pearson JT
Biochem Pharmacol; 2017 Nov; 144():90-99. PubMed ID: 28789938
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Toblli JE; Cao G; Giani JF; Muñoz MC; Angerosa M; Dominici FP
J Hypertens; 2011 Aug; 29(8):1613-23. PubMed ID: 21720265
[TBL] [Abstract][Full Text] [Related]
10. Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.
Dudkowski C; Karim A; Zhao Z; Alonso AB; Garg D; Preston RA
J Clin Pharmacol; 2018 Jan; 58(1):48-56. PubMed ID: 28750149
[TBL] [Abstract][Full Text] [Related]
11. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
12. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial.
Collier DJ; Juhasz A; Agabiti-Rosei E; Lloyd E; Hisada M; Zhao L; Kupfer S; Caulfield MJ
J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1473-1484. PubMed ID: 30302936
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
15. Increased aldosterone levels in a model of type 2 diabetes mellitus.
Fredersdorf S; Endemann DH; Luchner A; Heitzmann D; Ulucan C; Birner C; Schmid P; Stoelcker B; Resch M; Muders F; Riegger GA; Weil J
Exp Clin Endocrinol Diabetes; 2009 Jan; 117(1):15-20. PubMed ID: 18726873
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Mizuno M; Sada T; Kato M; Koike H
Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
[TBL] [Abstract][Full Text] [Related]
17. Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats.
Ito D; Cao P; Kakihana T; Sato E; Suda C; Muroya Y; Ogawa Y; Hu G; Ishii T; Ito O; Kohzuki M; Kiyomoto H
PLoS One; 2015; 10(9):e0138037. PubMed ID: 26379244
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Bakris GL; Sica D; White WB; Cushman WC; Weber MA; Handley A; Song E; Kupfer S
Am J Med; 2012 Dec; 125(12):1229.e1-1229.e10. PubMed ID: 22939358
[TBL] [Abstract][Full Text] [Related]
19. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
Mizuno M; Sada T; Kato M; Fukushima Y; Terashima H; Koike H
J Cardiovasc Pharmacol; 2006 Oct; 48(4):135-42. PubMed ID: 17086090
[TBL] [Abstract][Full Text] [Related]
20. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
Nakano R; Kurosaki E; Shimaya A; Kajikawa S; Shibasaki M
Eur J Pharmacol; 2006 Nov; 549(1-3):185-91. PubMed ID: 16989806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
